Literature DB >> 14671484

Evaluation of educational programs in inflammatory bowel disease.

Hude Quan1, Jane W Present, Lloyd R Sutherland.   

Abstract

BACKGROUND: Little is known about the status of patient knowledge in inflammatory bowel disease (IBD) and potential benefit of educational programs. The authors conducted this study to assess 1) the knowledge of IBD of participants attending educational workshops offered to the public and 2) the effect of the workshop on participants' knowledge level.
METHODS: Workshops on IBD were offered to the public at nine communities in the United States. Each workshop consisted of a combination of 3 hours of presentations and question-and-answer sessions. Participants, including patients with IBD and their parents, spouses, siblings, friends, and significant others, were asked to complete the Crohn's and Colitis Knowledge Score questionnaires just before (Q1) and immediately after (Q2) the workshop and approximately 3 months later (Q3). The authors scored one point for each correct answer to the 30 questions in the Crohn's and Colitis Knowledge Score.
RESULTS: Of the 734 who completed the Q1, 33.7% gave correct answers for questions about IBD complications, 36.2% for treatment, 61.4% for general knowledge, and 64.8% for diet. After the workshop, the proportion for these four knowledge areas increased by 11.0% to 19%. For the participants who completed all of the three questionnaires and answered all the 30 questions (N=59), the mean score was 18 at Q1, 22 at Q2 (p<0.001, Q2 vs. Q1), and 21 at Q3 (p<0.001, Q3 vs. Q1).
CONCLUSIONS: The public's general knowledge of IBD is low. Educational programs oriented toward IBD improve participant's knowledge, and the knowledge they acquired is retained for at least 3 months.

Entities:  

Mesh:

Year:  2003        PMID: 14671484     DOI: 10.1097/00054725-200311000-00003

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Knowledge of disease and health information needs of the patients with inflammatory bowel disease in a developing country.

Authors:  Mohammadreza Rezailashkajani; Delnaz Roshandel; Shahin Ansari; Mohammad Reza Zali
Journal:  Int J Colorectal Dis       Date:  2005-08-19       Impact factor: 2.571

2.  Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 Year.

Authors:  Ameer Abutaleb; Andrea Buchwald; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

3.  Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease.

Authors:  Anilga Moradkhani; Lauren Kerwin; Sharon Dudley-Brown; James H Tabibian
Journal:  Dig Dis Sci       Date:  2011-05-03       Impact factor: 3.199

4.  The Level of Public Knowledge about Inflammatory Bowel Disease in Christchurch, New Zealand.

Authors:  Angharad Vernon-Roberts; Richard B Gearry; Andrew S Day
Journal:  Inflamm Intest Dis       Date:  2020-09-16

5.  Disease-Related Knowledge and Information Needs Among Inflammatory Bowel Disease Patients in Korea.

Authors:  Yang-Sook Yoo; Ok-Hee Cho; Kyeong-Sook Cha
Journal:  Gastroenterol Nurs       Date:  2015 Nov-Dec       Impact factor: 0.978

6.  The Telemedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participants' Perceptions.

Authors:  Charlene Connolly Quinn; Sarah Chard; Katharine M Russman; Raymond K Cross; Erin G Roth; J Kevin Eckert
Journal:  J Med Internet Res       Date:  2019-06-03       Impact factor: 5.428

7.  Disease knowledge after an educational program in patients with GERD--a randomized controlled trial.

Authors:  Jorgen Urnes; Hermod Petersen; Per G Farup
Journal:  BMC Health Serv Res       Date:  2008-11-13       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.